Abstract

BackgroundBlastocyst biopsy has become the most mainstream biopsy method. Currently, there are two blastocyst biopsy strategies. Many studies have compared the advantages and disadvantages between blastomere and blastocyst biopsy, but fewer articles have compared the two blastocyst biopsy strategies. For the moment, no published studies have explored the entire set of information on embryo development, next-generation sequencing results, and clinical outcomes, including the baby’s health status with the two blastocyst biopsy strategies.MethodsA total of 323 preimplantation genetic testing cycles from April 2018 to May 2020, including 178 cycles with Strategy A and 145 cycles with Strategy B. Strategy A was to create a laser-assisted zona pellucid opening for cleavage embryo on the third day after insemination, but Strategy B was not. Strategy A performed a biopsy for artificially assisted hatching blastocysts, while Strategy B performed a biopsy for expanded blastocysts on day 5 or 6. In this study, embryo development, next-generation sequencing results, pregnancy outcomes, and offspring health of the two strategies were compared and analyzed.ResultsThere were no statistical differences between the two groups in the rate of fertilization, blastocyst and abortion. The rate of cleavage from Strategy A was slightly higher than Strategy B, and the rate of high-quality cleavage embryo was lower than Strategy B, while the rate of high-quality blastocyst was higher than Strategy B. The rate of no-results blastocyst was significantly lower than Strategy B. In particular, the rate of biochemical pregnancy, clinical pregnancy, and live birth of Strategy A were significantly lower than those of Strategy B. The average Apgar scores of newborns were ≥8 in both groups, and there was no significant difference in average height and weight. In Strategy A, a baby was born with thumb syndactyly, and Strategy B had no congenital disabilities.ConclusionsBlastocyst biopsy strategy without laser-assisted zona pellucid drilling on day 3 achieves better clinical treatment effects. Therefore, Strategy B is an optimal treatment regime for PGT.

Highlights

  • Preimplantation genetic testing (PGT) is one of the essential techniques in human-assisted reproductive technology (ART), which contributes to reducing the transmission of genetic diseases

  • We practiced a total of 323 preimplantation genetic testingthawed embryo transfer (PGT-TET) cycles at Reproductive Medicine Center of the First Affiliated Hospital of Anhui Medical University, from April 2018 to May 2020

  • Most patients were diagnosed with chromosomal abnormalities in one or both partners; recurrent miscarriage; abnormal gestation and birth or teratozoospermia

Read more

Summary

Introduction

Preimplantation genetic testing (PGT) is one of the essential techniques in human-assisted reproductive technology (ART), which contributes to reducing the transmission of genetic diseases. PGT is to identify embryos with normal chromosomes for transfer, containing Preimplantation genetic testing for aneuploidy (PGT-A), Preimplantation genetic testing for monogenic/single gene defects (PGT-M), and Preimplantation genetic testing for structural rearrangements (PGT-SR). It can significantly increase the success rate of ART. Recent studies have extracted DNA and blastocoel fluid from the conditioned blastocyst culture medium to verify the euploidy of chromosomes. In this way, non-invasive preimplantation genetic screening can be realized [5, 6]. No published studies have explored the entire set of information on embryo development, next-generation sequencing results, and clinical outcomes, including the baby’s health status with the two blastocyst biopsy strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call